Revenue Breakdown
Composition ()
No data
Revenue Streams
Axsome Therapeutics Inc (AXSM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Auvelitv, accounting for 79.6% of total sales, equivalent to $136.10M. Other significant revenue streams include Sunosi and Symbravo. Understanding this composition is critical for investors evaluating how AXSM navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Axsome Therapeutics Inc maintains a gross margin of 92.89%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -18.38%, while the net margin is -14.57%. These profitability ratios, combined with a Return on Equity (ROE) of -252.11%, provide a clear picture of how effectively AXSM converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, AXSM competes directly with industry leaders such as HALO and KRYS. With a market capitalization of $8.51B, it holds a leading position in the sector. When comparing efficiency, AXSM's gross margin of 92.89% stands against HALO's 77.39% and KRYS's 93.85%. Such benchmarking helps identify whether Axsome Therapeutics Inc is trading at a premium or discount relative to its financial performance.
